US generics company wins patent battle over Merck Serono’s blockbuster MS drug

Merck Serono has failed to convince a US appeals court to overturn a PTAB decision invalidating two dosing regimen patents for cladribine.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Eisai and Merck shield blockbuster cancer drug from generic challenge

29 May 2025 Shilpa Medicare failed to prove invalidity of patent covering Lenvima | Eisai says ruling keeps India-based generic maker’s product off the market until 2036.

Europe

UK court upholds EU SPC precedent, rejecting MSD’s appeal

30 January 2025 UK court confirms it cannot depart from CJEU law | SPC application for multiple sclerosis treatment rejected | Judges stress that any change to the SPC framework needs legislative reform not interpretation.

More features

Novartis counsel warns: ‘Don’t let AI develop without our input’

Squires: ‘Inherited patent backlog was an absolute dumpster fire’

Delegates descend upon Washington, DC for AIPLA Annual Meeting

Novo Nordisk counters rival with $9bn bid for obesity drug developer

‘We're being attacked from all sides’: Thermo Fisher Scientific counsel

China trademarks rankings reveal new entries, hidden gems and big brands

Edwards defends key heart valve product from infringement threat

Is AI emerging as the ‘fourth party’ solving billion-dollar disputes?

US generics company wins patent battle over Merck Serono’s blockbuster MS drug

More on this story

Editor's picks

Editor's picks

More features